查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654360

全球半固態劑量 CDMO 市場：市場規模、佔有率、趨勢分析（按給藥途徑、產品、服務、最終用途和地區）、細分市場預測（2025-2030 年）

Semi-Solid Dosage CDMO Market Size, Share & Trends Analysis Report By Route of Administration (Topical, Transdermal), By Product, By Service, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 145 Pages | 商品交期: 2-10個工作天內

價格

半固態劑量 CDMO 市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球半固態劑量CDMO市場規模預計到2030年將達到674億美元，2025年至2030年期間的複合年成長率為11.90%。

全球半固態劑量 CDMO 市場規模的成長受到個人化醫療日益成長的趨勢以及對創新藥物輸送系統日益成長的需求的推動。半固態製劑如乳膏、凝膠和軟膏因易於塗抹、吸收迅速而更受患者青睞。此外，它在皮膚病治療中也被廣泛採用，以增加患者的治療選擇。根據美國皮膚病學會 2024 年 9 月發布的資料，痤瘡是美國最常見的疾病，每年影響約 5,000 萬人。此外，其中85％的年齡在12歲至24歲之間。因此，皮膚病發病率的不斷上升導致對外用製劑開發的需求增加，從而推動對 CDMO 擴大其半固態製劑能力的需求。

此外，配方和製造流程的持續技術進步也推動了半固態劑型市場的發展。奈米技術和先進的乳化技術等創新正在提高半固態劑型的功效和穩定性。這些進步使 CDMO 能夠生產符合嚴格監管要求的更高品質的產品，從而吸引更多客戶。例如，乳化的發展提高了活性成分的生物利用度，使得半固態製劑能夠更有效地用於治療各種疾病，包括慢性疼痛和發炎疾病。

此外，慢性病盛行率不斷上升加上人口老化也促進了半固態劑量 CDMO 市場的成長。隨著越來越多的人尋求治療關節炎、糖尿病和皮膚病等疾病，對有效半固態的需求預計在未來幾年將會成長。這一趨勢在老年護理中尤其明顯，半固態製劑由於易於使用而更受青睞。因此，這些因素進一步促進了市場的成長。

半固態劑型 CDMO 市場：概覽

  • 按產品分類，外用藥物將佔據市場主導地位，到 2024 年將佔有 88.53% 的佔有率。這些配方對於局部治療特別有效且是皮膚科應用的理想選擇。
  • 根據給藥途徑，乳膏/乳液部分將在 2024 年佔據半固態劑量 CDMO 行業的主導地位，佔有率為 42.49%。這些配方具有獨特的優勢，如易於使用、質地宜人、皮膚吸收性更強，從而促進了這一領域的成長。
  • 按服務分類，契約製造部門在 2024 年佔據了最大的收入佔有率。製藥公司擴大將製造流程委託給 CDMO，以便專注於研發等核心競爭力。
  • 根據最終用途，製藥部門在 2024 年佔據了最大的收益佔有率。這是因為對創新治療解決方案的需求不斷成長，從而推動公司增加對開發新藥的投資。
  • 2024 年北美佔據市場主導地位，佔有率為 41.37%。市場擴張的動力源於該地區慢性病發病率的上升，刺激了對先進治療解決方案的需求。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

3. 半固態劑型 CDMO 市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 半固態劑型 CDMO 市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析
    • COVID-19影響分析

第 4 章半固態劑量 CDMO 市場：按給藥途徑的估計和趨勢分析

  • 給藥途徑：分段儀表板
  • 半固態劑型 CDMO 市場：依給藥途徑進行的變化分析
  • 依給藥途徑分類（2018-2030 年）
  • 外用藥物
    • 局部製劑：半固態製劑 CDMO 市場（2018-2030 年）
  • 經皮吸收劑
    • 經皮藥：半固態藥物 CDMO 市場（2018-2030 年）
  • 其他
    • 其他半固態劑型 CDMO 市場（2018-2030 年）

第 5 章半固態劑型 CDMO 市場：按產品分類的估計和趨勢分析

  • 產品：細分儀表板
  • 半固態劑型 CDMO 市場：依產品進行差異分析
  • 按產品（2018 - 2030 年）
  • 軟膏
    • 軟膏：半固態劑型 CDMO 市場（2018-2030 年）
  • 乳霜和乳液
    • 乳霜與乳液：半固態劑型 CDMO 市場（2018-2030 年）
  • 貼上
    • 糊劑：半固態劑型 CDMO 市場（2018-2030 年）
  • 凝膠
    • 凝膠：半固態劑型 CDMO 市場（2018-2030 年）
  • 其他
    • 其他：半固態劑型 CDMO 市場（2018-2030 年）

第 6 章半固態劑型 CDMO 市場：按服務分類的估計和趨勢分析

  • 服務：細分儀表板
  • 半固態劑型 CDMO 市場：依服務進行差異分析
  • 依服務分類（2018-2030 年）
  • 合約開發
    • 合約開發：半固態劑型 CDMO 市場（2018-2030 年）
  • 契約製造
    • 契約製造：半固態劑量 CDMO 市場（2018-2030 年）

7. 半固態劑型 CDMO 市場：以最終用途進行的估計和趨勢分析

  • 最終用途：分段式儀表板
  • 半固態劑型 CDMO 市場：依最終用途進行差異分析
  • 依最終用途分類（2018-2030 年）
  • 製藥公司
    • 製藥公司：半固態劑型 CDMO 市場（2018-2030 年）
  • 生物製藥公司
    • 生物製藥公司：半固態劑型 CDMO 市場（2018-2030 年）
  • 其他
    • 其他：半固態劑型 CDMO 市場（2018-2030 年）

8. 半固態劑型 CDMO 市場：按地區分類的估計和趨勢分析

  • 各地區市場佔有率分析（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 全球市場概況：按地區
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 丹麥
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 泰國
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 公司分類
  • 各公司市場佔有率分析（2024 年）
  • 公司簡介
    • The Lubrizol Corporation
    • Cambrex Corporation
    • Contract Pharmaceuticals Limited.
    • Bora Pharmaceutical
    • Ascendia Pharmaceuticals
    • Pierre Fabre group
    • Piramal Pharma Solutions
    • DPT Laboratories, LTD
    • LGM Pharma
    • Pace Analytical Life Sciences, LLC.
Product Code: GVR-4-68040-477-4

Semi-Solid Dosage CDMO Market Growth & Trends:

The global semi-solid dosage CDMO market size is estimated to reach USD 67.40 billion by 2030, expanding at a CAGR of 11.90% from 2025 to 2030, according to a new report by Grand View Research, Inc. The global semi-solid dosage CDMO market size is driven due to growing trend towards personalized medicine coupled with increasing demand for innovative drug delivery systems. Patients prefer semi-solid formulations, such as creams, gels, and ointments, due to their ease of application and rapid absorption. Moreover, it has significant adoption for dermatological treatments to enhance patient treatment options. According to the data published by the American Academy of Dermatology Association in September 2024, Acne is the most common condition affecting approximately 50 million people in the U.S. annually. Moreover, 85% of the people are among age 12 to 24. Thus, increasing prevalence of skin disorders has led to an increasing demand for the development of topical formulations, consequently driving the demand for CDMOs to expand their capabilities in semi-solid dosage forms.

Furthermore, constant technological advancements in formulation and manufacturing processes have also propelled the semi-solid dosage market. Innovations such as nanotechnology and advanced emulsion techniques have improved the efficacy and stability of semi-solid formulations. These advancements enable CDMOs to produce high-quality products that meet stringent regulatory requirements, thereby attracting more clients. For instance, the development of nano-emulsions has enhanced the bioavailability of active ingredients, making semi-solid formulations more effective in treating various conditions, including chronic pain and inflammatory diseases.

In addition, increasing prevalence of chronic diseases, coupled with an aging population, is also contributing to the growth of the semi-solid dosage CDMO market. As more individuals seek treatments for conditions such as arthritis, diabetes, and skin disorders, the demand for effective semi-solid formulations is projected to increase in the coming years. This trend is particularly prominent in geriatric care, where semi-solid forms are often preferred due to their ease of use. Thus, these factors are further contributing to the market growth.

Semi-Solid Dosage CDMO Market Report Highlights:

  • Based on product, topical segment dominated in the market with a share of 88.53% in 2024. These formulations are particularly effective for localized treatments, making them ideal for dermatological applications
  • Based on rout of administration, the creams and lotions segment dominated the semi-solid dosage CDMO industry with 42.49% share in 2024. These formulations offer unique benefits such as ease of application, pleasant texture, and enhanced skin absorption which is contributing to the segment's growth
  • Based on service, the contract manufacturing segment accounted for the largest revenue share in 2024. Pharmaceutical companies are increasingly outsourcing their manufacturing processes to CDMOs to focus on core competencies such as research and development
  • Based on end use, the pharmaceutical companies segment accounted for the largest revenue share in 2024 owing to the increasing demand for innovative therapeutic solutions which has resulted into the increasing investment by the companies for the development of new drugs
  • North America dominated the market with a share of 41.37% in 2024. The increasing prevalence of chronic diseases and increasing demand for advanced therapeutic solutions in the region are propelling market expansion

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Route of Administration
    • 1.2.2. Product
    • 1.2.3. Service
    • 1.2.4. End Use
  • 1.3. Regional Scope
  • 1.4. Estimates And Forecast Timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations
  • 1.12. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Semi-Solid Dosage CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Semi-Solid Dosage CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Semi-Solid Dosage CDMO Market: Route of Administration Estimates & Trend Analysis

  • 4.1. Route of Administration: Segment Dashboard
  • 4.2. Semi-Solid Dosage CDMO Market, By Route of Administration: Movement Analysis
  • 4.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Route of Administration, 2018 - 2030
  • 4.4. Topical
    • 4.4.1. Topical Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 4.5. Transdermal
    • 4.5.1. Transdermal Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Semi-Solid Dosage CDMO Market: Product Estimates & Trend Analysis

  • 5.1. Product: Segment Dashboard
  • 5.2. Semi-Solid Dosage CDMO Market, By Product: Movement Analysis
  • 5.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Product, 2018 - 2030
  • 5.4. Ointments
    • 5.4.1. Ointments Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 5.5. Creams and Lotions
    • 5.5.1. Creams and Lotions Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 5.6. Pastes
    • 5.6.1. Pastes Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 5.7. Gels
    • 5.7.1. Gels Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 6. Semi-Solid Dosage CDMO Market: Service Estimates & Trend Analysis

  • 6.1. Service: Segment Dashboard
  • 6.2. Semi-Solid Dosage CDMO Market, By Service: Movement Analysis
  • 6.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Service, 2018 - 2030
  • 6.4. Contract Development
    • 6.4.1. Contract Development Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 6.5. Contract Manufacturing
    • 6.5.1. Contract Manufacturing Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 7. Semi-Solid Dosage CDMO Market: End Use Estimates & Trend Analysis

  • 7.1. End Use: Segment Dashboard
  • 7.2. Semi-Solid Dosage CDMO Market, By End Use: Movement Analysis
  • 7.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By End Use, 2018 - 2030
  • 7.4. Pharmaceutical Companies
    • 7.4.1. Pharmaceutical Companies Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 7.5. Biopharmaceutical Companies
    • 7.5.1. Biopharmaceutical Companies Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 8. Semi-Solid Dosage CDMO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. North America
    • 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Mexico Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.5. Europe
    • 8.5.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. UK Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Germany Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. France Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Italy Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Spain Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.7. Sweden
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Sweden Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Denmark Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Norway Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.6. Asia Pacific
    • 8.6.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Japan Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. India Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.5. Thailand
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Thailand Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. South Korea Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.7. Australia
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Australia Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.7. Latin America
    • 8.7.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Brazil Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.8. MEA
    • 8.8.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. South Africa Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Saudi Arabia Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. UAE Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Kuwait Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Share Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. The Lubrizol Corporation
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Cambrex Corporation
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Contract Pharmaceuticals Limited.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Bora Pharmaceutical
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Ascendia Pharmaceuticals
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Pierre Fabre group
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Piramal Pharma Solutions
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. DPT Laboratories, LTD
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. LGM Pharma
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Pace Analytical Life Sciences, LLC.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 4 Global Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 5 Global Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 6 Global Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 7 Global Semi-Solid Dosage CDMO, by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 11 North America Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 12 North America Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 13 U.S. Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 15 U.S. Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 16 U.S. Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 17 Canada Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Canada Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 19 Canada Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 20 Canada Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 21 Mexico Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Mexico Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 23 Mexico Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 24 Mexico Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 25 Europe Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 26 Europe Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 Europe Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 28 Europe Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 29 Europe Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 30 UK Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 UK Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 32 UK Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 33 UK Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 34 Germany Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Germany Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 36 Germany Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 37 Germany Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 38 France Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 France Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 40 France Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 41 France Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 42 Italy Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Italy Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 44 Italy Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 45 Italy Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 46 Spain Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 47 Spain Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 48 Spain Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 49 Spain Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 50 Denmark Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 Denmark Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 52 Denmark Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 53 Denmark Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Sweden Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 Sweden Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 56 Sweden Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 57 Sweden Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 58 Norway Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 59 Norway Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 60 Norway Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 61 Norway Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 67 Japan Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Japan Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 69 Japan Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 70 Japan Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 71 China Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 72 China Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 73 China Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 74 China Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 75 India Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 76 India Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 77 India Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 78 India Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 79 Thailand Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 80 Thailand Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 81 Thailand Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 82 Thailand Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 83 South Korea Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 84 South Korea Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 85 South Korea Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 86 South Korea Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 87 Australia Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 88 Australia Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 89 Australia Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 90 Australia Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 91 Latin America Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 92 Latin America Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 93 Latin America Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 94 Latin America Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 95 Latin America Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 96 Brazil Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 97 Brazil Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 98 Brazil Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 99 Brazil Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 100 Argentina Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 101 Argentina Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 102 Argentina Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 103 Argentina Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 109 South Africa Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 110 South Africa Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 111 South Africa Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 112 South Africa Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 117 UAE Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 118 UAE Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 119 UAE Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 120 UAE Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 124 Kuwait Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Semi-Solid Dosage CDMO Market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 Semi-Solid Dosage CDMO Market snapshot
  • Fig. 11 Semi-Solid Dosage CDMO Market driver impact
  • Fig. 12 Semi-Solid Dosage CDMO Market restraint impact
  • Fig. 13 Semi-Solid Dosage CDMO sector Route of administration takeaways (USD Million)
  • Fig. 14 Semi-Solid Dosage CDMO Market: Route of administration movement analysis
  • Fig. 15 Topical market, 2018 - 2030 (USD Million)
  • Fig. 16 Transdermal market, 2018 - 2030 (USD Million)
  • Fig. 17 Others market, 2018 - 2030 (USD Million)
  • Fig. 18 Semi-Solid Dosage CDMO sector Product takeaways (USD Million)
  • Fig. 19 Semi-Solid Dosage CDMO Market: Product movement analysis
  • Fig. 20 Ointments market, 2018 - 2030 (USD Million)
  • Fig. 21 Creams and Lotions market, 2018 - 2030 (USD Million)
  • Fig. 22 Pastes market, 2018 - 2030 (USD Million)
  • Fig. 23 Gels market, 2018 - 2030 (USD Million)
  • Fig. 24 Others market, 2018 - 2030 (USD Million)
  • Fig. 25 Semi-Solid Dosage CDMO sector Service takeaways (USD Million)
  • Fig. 26 Semi-Solid Dosage CDMO Market: Service movement analysis
  • Fig. 27 Contract Development market, 2018 - 2030 (USD Million)
  • Fig. 28 Contract Manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 29 Semi-Solid Dosage CDMO sector End Use takeaways (USD Million)
  • Fig. 30 Semi-Solid Dosage CDMO Market: End Use movement analysis
  • Fig. 31 Pharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 32 Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 33 Others market, 2018 - 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional outlook, 2024 & 2030
  • Fig. 36 North America Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 38 Canada Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 41 UK Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 42 Germany Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 43 France Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 45 Spain companion animal Health market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 47 Denmark Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 48 Norway Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 49 Asia Pacific Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 50 Japan Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 51 China Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 52 India Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 54 South Korea Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 55 Australia Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 56 Latin America Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 57 Brazil Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 58 Argentina Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 59 Middle East & Africa Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 60 South Africa Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 61 Saudi Arabia Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 62 UAE Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 63 Kuwait Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 64 Market participant categorization